PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?

Published:2024-07 Issue: Volume:105 Page:105218
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Bakouny Ziad^ORCID,Braun David A.,Reznik Ed,Hakimi A. Ari

Publisher

Elsevier BV

Reference10 articles.

1. Cancer statistics, 2024;Siegel;CA Cancer J Clin,2024

2. Novel targeted therapies for renal cell carcinoma: building on the successes of vascular endothelial growth factor and mTOR inhibition;Saliby;Hematol Oncol Clin North Am,2023

3. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma;Braun;Nat Rev Clin Oncol,2021

4. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response;Xu;eBioMedicine,2024

5. PAK4 signaling in health and disease: defining the PAK4–CREB axis;Won;Exp Mol Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP